SCHEMBL22972009

SCHEMBL22972009

COC(=O)c1cc(OC)cc(Oc2ccnc3ccccc23)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDR2 Q16832 1/20 0.56
KDR P35968 6/20 0.47
PDGFRA P16234 5/20 0.47
BRAF P15056 1/20 0.45
MAPK14 Q16539 1/20 0.45
TNNI3K Q59H18 1/20 0.45
MET P08581 2/20 0.45
AURKA O14965 1/20 0.45
TEK Q02763 1/20 0.45
AURKB Q96GD4 1/20 0.45
AXL P30530 2/20 0.44
KIT P10721 1/20 0.44
TSHR P16473 1/20 0.44
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29317841 0.94 USP2 (0.49) DDR2KDRPDGFRABRAFMAPK14
SCHEMBL30050285 0.89 DDR2 (0.54) DDR2KDRPDGFRABRAFMAPK14
SCHEMBL22972145 0.89 DDR2 (0.54) DDR2KDRPDGFRABRAFMAPK14
SCHEMBL30049303 0.88 DDR2 (0.54) DDR2KDRPDGFRAMETAURKA
SCHEMBL29318681 0.88 DDR2 (0.54) DDR2KDRPDGFRAMETAURKA
SCHEMBL29317823 0.87 DDR2 (0.54) DDR2PDGFRABRAFHTT
SCHEMBL30049538 0.83 DDR2 (0.79) DDR2KDRPDGFRABRAFMAPK14
SCHEMBL29317838 0.83 DDR2 (0.79) DDR2KDRPDGFRABRAFMAPK14
SCHEMBL22972185 0.81 ALDH1A1 (0.58) DDR2HDAC1KDM4ELMNAHTT
SCHEMBL29633203 0.81 ALDH1A1 (0.58) DDR2HDAC1KDM4ELMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CHENGDU ANTICANCER BIOSCIENCE LTD (CN) 2024-07-18 US disclosed
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CHENGDU ANTICANCER BIOSCIENCE LTD (CN) 2024-07-18 US disclosed
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CHENGDU ANTICANCER BIOSCIENCE LTD (CN) 2024-07-18 US disclosed
CN-117321036-A phenyl-O-quinoline, quinazoline, thienopyridine, thienopyrimidine, pyrrolopyridine, pyrrolopyrimidine compounds having anticancer activity 成都安泰康赛生物科技有限公司 2023-12-29 CN disclosed
US-20220388979-A1 QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS B.C.I. PHARMA (BE) 2022-12-08 US disclosed
WO-2021023888-A1 ISOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS B.C.I. PHARMA (BE) 2021-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220388979-A1 QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS ABL1, PHKB, EEF2K DDR2 1289/4885KDR 604/4885PDGFRA 992/4885
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CYP27A1, CPT1A, OAT DDR2 4341/4885KDR 4885/4885PDGFRA 4710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.